Advanced Biological Laboratories (ABL) S.A. agreed to acquire 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons for €3.9 million on October 15, 2021. As of June 14, 2022, Advanced Biological Laboratories (ABL) S.A signed a definitive agreement to acquire 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons. Advanced Biological Laboratories acquired 0.24 million shares of ABL Diagnostics at €15.9 per share. STE Parisienne De Construction Et De Location sold 91.47% stake and seven natural persons sold 5.22% stake. The transaction is subject to shareholder approval of ABL Diagnostics Société anonyme. As of June 13, 2022, Board of Directors of ABL Diagnostics have approved the transaction. As of August 31, 2022, the transaction has been approved by the shareholders of ABL Diagnostics and fulfilled all conditions. Atout Capital advised the shareholders of ABL Diagnostics on the sale of their control block to Advanced Biological Laboratories.

Advanced Biological Laboratories (ABL) S.A. completed the acquisition of a 96.7% stake in ABL Diagnostics Société anonyme (ENXTPA : ABLD) from STE Parisienne De Construction Et De Location and seven natural persons on August 31, 2022.